Vera Therapeutics, Inc. (VERA) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $34.78: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 7.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 1.47; Below-average business quality.
Vera Therapeutics is a late clinical-stage biotech developing atacicept (TACI-Fc dual BAFF/APRIL inhibitor) for IgAN, with a BLA granted Priority Review (PDUFA July 7, 2026), plus MAU868 for BK viremia and VT-109 (preclinical). No products approved; $714.6M cash as of December... Read more
Sell if holding. Engine safety override at $34.78: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 7.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 1.47; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 52. Score 5.0/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Vera Therapeutics, Inc.
Latest news
- NEWS Vera Moves Up Key FDA Review Timeline for Kidney Disease Drug, Expects Critical Trial Results in Third Quarter of 2026 — benzinga Jun 2, 2026 positive
- NEWS Evercore ISI Group Maintains Outperform on Vera Therapeutics, Lowers Price Target to $91 — benzinga May 15, 2026 positive
- NEWS Vera Therapeutics Q1 EPS $(1.69) Misses $(1.34) Estimate — benzinga May 7, 2026 negative
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $34.78: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 7.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 1.47; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 52. Prior stop was $32.35. Score 5.0/10, moderate confidence.
Take-profit target: $67.86 (+95.1% upside). Prior stop was $32.35. Stop-loss: $32.35.
Quality below floor (1.6 < 4.0).
Vera Therapeutics, Inc. trades at a P/E of N/A (forward -9.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts cover VERA with a consensus score of 4.3/5. Average price target: $78.
What does Vera Therapeutics, Inc. do?Vera Therapeutics is a late clinical-stage biotech developing atacicept (TACI-Fc dual BAFF/APRIL inhibitor) for IgAN,...
Vera Therapeutics is a late clinical-stage biotech developing atacicept (TACI-Fc dual BAFF/APRIL inhibitor) for IgAN, with a BLA granted Priority Review (PDUFA July 7, 2026), plus MAU868 for BK viremia and VT-109 (preclinical). No products approved; $714.6M cash as of December 31, 2025. Atacicept is in-licensed from Ares Trading S.A. with worldwide commercialization rights.